ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 300 filers reported holding ACADIA PHARMACEUTICALS INC in Q2 2020. The put-call ratio across all filers is 1.07 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $367,201 | -14.3% | 17,620 | -1.5% | 0.03% | -12.9% |
| Q2 2023 | $428,346 | +27.3% | 17,885 | 0.0% | 0.03% | +29.2% |
| Q1 2023 | $336,596 | +18.2% | 17,885 | 0.0% | 0.02% | +9.1% |
| Q4 2022 | $284,729 | -2.8% | 17,885 | 0.0% | 0.02% | -8.3% |
| Q3 2022 | $293,000 | +16.3% | 17,885 | 0.0% | 0.02% | +20.0% |
| Q2 2022 | $252,000 | -41.9% | 17,885 | -0.1% | 0.02% | -31.0% |
| Q1 2022 | $434,000 | +3.8% | 17,910 | 0.0% | 0.03% | +7.4% |
| Q4 2021 | $418,000 | +40.7% | 17,910 | 0.0% | 0.03% | +28.6% |
| Q3 2021 | $297,000 | -32.0% | 17,910 | 0.0% | 0.02% | -38.2% |
| Q2 2021 | $437,000 | -5.2% | 17,910 | +0.1% | 0.03% | -22.7% |
| Q1 2021 | $461,000 | -53.2% | 17,885 | -3.0% | 0.04% | -56.9% |
| Q4 2020 | $985,000 | +24.4% | 18,429 | -4.0% | 0.10% | +67.2% |
| Q3 2020 | $792,000 | -8.9% | 19,204 | +7.2% | 0.06% | -53.4% |
| Q2 2020 | $869,000 | -7.8% | 17,920 | -18.7% | 0.13% | +10.1% |
| Q4 2019 | $943,000 | – | 22,042 | – | 0.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Baker Brothers Advisors | 25,819,768 | $972,631,000 | 7.89% |
| SECTORAL ASSET MANAGEMENT INC | 822,392 | $30,980,000 | 3.99% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 240,773 | $9,068,000 | 3.53% |
| HARVEY CAPITAL MANAGEMENT INC | 230,700 | $8,690,000 | 3.51% |
| Palo Alto Investors LP | 1,641,030 | $61,818,000 | 2.60% |
| GARRISON BRADFORD & ASSOCIATES INC | 73,350 | $2,763,000 | 2.31% |
| EMORY UNIVERSITY | 52,977 | $1,996,000 | 1.58% |
| Sivik Global Healthcare LLC | 120,000 | $4,520,000 | 1.54% |
| Stanley-Laman Group, Ltd. | 143,876 | $5,420,000 | 1.45% |
| ACUTA CAPITAL PARTNERS, LLC | 170,000 | $6,404,000 | 1.15% |